Browsing Tag
Medicines and Healthcare products Regulatory Agency
13 posts
Lupin adds Yuvezzi to €190m VISUfarma bet as European ophthalmology strategy takes shape
Lupin has secured exclusive Yuvezzi rights across major European markets through VISUfarma, extending its €190 million ophthalmology investment into a differentiated prescription therapy that still requires regional approvals.
Fate Therapeutics bets on outpatient CAR T as FT819 enters potentially registrational study
FT819 enters a potentially registrational lupus nephritis trial with outpatient dosing as Fate tests whether off-the-shelf CAR T can scale.
Cytokinetics secures UK approval and NHS access for aficamten in obstructive HCM
UK approval and NICE reimbursement give aficamten access to 6,600 patients as Cytokinetics expands its global HCM commercial launch.
MedPal AI raises £5m as MPAL buys eMAR software and backs oral Wegovy launch
MedPal AI is combining pharmacy dispensing, care-home medication software and a private weight-loss clinic, but a 25% share-count expansion raises the execution bar.
Could pediatric anaphylaxis become the next growth opportunity for ALK Abelló’s EURneffy franchise?
Find out how EURneffy’s UK pediatric approval could strengthen ALK Abelló’s allergy strategy and challenge auto-injectors.
MHRA weight-loss drug raid exposes black-market risk behind Britain’s slimming jab boom
Weight-loss jabs are booming, and criminals are following demand. The MHRA raid shows how illicit supply is becoming a patient safety threat.
Novo Nordisk gets UK nod for single-dose Wegovy 7.2mg pen in obesity care
MHRA has approved the single-dose Wegovy 7.2mg pen for adults with obesity in the United Kingdom. Read what it means for patients and Novo Nordisk.
Can weight loss drugs cause fatal pancreas illness? UK raises red flag on GLP-1 therapies
UK strengthens pancreatitis risk warning for GLP-1 weight loss and diabetes drugs like Wegovy and Mounjaro. Find out what it means for health systems and pharma.
UK fast-tracks clinical trials with 14-day reviews and AI simulation support to regain R&D edge
Find out how MHRA’s 2026 trial reforms—fast-track routes, AI models, and 14-day reviews—aim to make the UK a global leader in clinical research again.
UK approves first-ever immunotherapy for type 1 diabetes — can teplizumab really delay onset by three years?
MHRA approves teplizumab, the UK’s first immunotherapy for type 1 diabetes, delaying onset by three years. See how it could reshape care pathways.